 | |
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1984 |
| Headquarters | Marlborough, Massachusetts, United States |
Key people | Antony Loebel (President and CEO) |
| Products | Latuda Aptiom Kynmobi Lonhala Magnair Lunesta |
| Parent | Sumitomo Pharma |
| Website | http://www.sunovion.com |
On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc.,[1] a biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.
Sunovion was founded as Sepracor, Inc. in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. Sepracor completed its initial public offering in 1991, trading on NASDAQ under the ticker SEPR. On October 12, 2010, Sepracor, Inc. was acquired by and became a standalone subsidiary of Sumitomo Pharma of Japan (then known as Sumitomo Dainippon Pharma). In April 2023, Sumitomo Pharma announced the combination of its U.S. subsidiaries, including Sunovion, to form Sumitomo Pharma America (SMPA).[2]
- ^ "Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities". Yahoo Finance. July 10, 2023. Archived from the original on July 13, 2023. Retrieved July 13, 2023.
- ^ Armstrong, Annalee (April 3, 2023). "Sumitomo Pharma tidies up 7 units into one combined US entity in spring cleaning". Fierce Biotech. Retrieved July 13, 2023.